BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perner F, Perner C, Ernst T, Heidel FH. Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells 2019;8:E854. [PMID: 31398915 DOI: 10.3390/cells8080854] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Mozzini C, Pagani M. Clonal Hematopoiesis and Cardiovascular Diseases: The Connection. Curr Probl Cardiol 2021;:100962. [PMID: 34391764 DOI: 10.1016/j.cpcardiol.2021.100962] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Schafer AI. Thrombotic, Vascular, and Bleeding Complications of the Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 2021;35:305-24. [PMID: 33641871 DOI: 10.1016/j.hoc.2020.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Barth E, Sieber P, Stark H, Schuster S. Robustness during Aging-Molecular Biological and Physiological Aspects. Cells 2020;9:E1862. [PMID: 32784503 DOI: 10.3390/cells9081862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yang T, Hu M, Qi W, Yang Z, Tang M, He J, Chen Y, Bai P, Yuan X, Zhang C, Liu K, Lu Y, Xiang M, Chen L. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms. J Med Chem 2019;62:10305-20. [DOI: 10.1021/acs.jmedchem.9b01348] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
5 Wang Z, Cai J, Cheng J, Yang W, Zhu Y, Li H, Lu T, Chen Y, Lu S. FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. J Med Chem 2021;64:2878-900. [PMID: 33719439 DOI: 10.1021/acs.jmedchem.0c01851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Song Y, Tang MY, Chen W, Wang Z, Wang SL. High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Dis Markers 2020;2020:7656031. [PMID: 33029256 DOI: 10.1155/2020/7656031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Stolyar MA, Gorbenko AS, Olkhovskiy IA, Bakhtina VI, Mikhalev MA, Olkhovik TI, Komarovskiy YY. Development of a method for the determination of the JAK2 gene mRNA in venous blood and assessment of its diagnostic value in oncohematology. Klin Lab Diagn 2021;66:379-84. [PMID: 34105916 DOI: 10.51620/0869-2084-2021-66-6-379-384] [Reference Citation Analysis]
8 Kiem D, Wagner S, Magnes T, Egle A, Greil R, Melchardt T. The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms. Int J Mol Sci 2021;22:9555. [PMID: 34502471 DOI: 10.3390/ijms22179555] [Reference Citation Analysis]
9 Shapira Cohen T, Chodick G, Steinberg DM, Grossman E, Shohat M, Salomon O. JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients. Thromb Haemost 2022. [PMID: 35288888 DOI: 10.1055/s-0042-1743470] [Reference Citation Analysis]
10 Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. Expert Opin Investig Drugs 2020;29:525-36. [PMID: 32693648 DOI: 10.1080/13543784.2020.1761323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
11 Salybekov AA, Wolfien M, Kobayashi S, Steinhoff G, Asahara T. Personalized Cell Therapy for Patients with Peripheral Arterial Diseases in the Context of Genetic Alterations: Artificial Intelligence-Based Responder and Non-Responder Prediction. Cells 2021;10:3266. [PMID: 34943774 DOI: 10.3390/cells10123266] [Reference Citation Analysis]
12 Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Int J Mol Sci 2021;22:2449. [PMID: 33671049 DOI: 10.3390/ijms22052449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
13 Gong X, Huang A. Differential expression and diagnostic significance of P53, MutS homologs 2, tropomyosin-4 in alpha-fetoprotein-negative hepatocellular carcinoma. J Clin Lab Anal 2020;34:e23353. [PMID: 32363617 DOI: 10.1002/jcla.23353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Li J, Wang C, Liu J, Yu Y, Liu Y, Peng Q, Liu H, Guan X. A feedback loop: Interactions between Inflammatory Signals and Clonal Hematopoiesis in Cardiovascular Disease. Mol Biol Rep 2021;48:3785-98. [PMID: 33987748 DOI: 10.1007/s11033-021-06370-5] [Reference Citation Analysis]
15 Heidel FH, Platzbecker U. The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies? Hemasphere 2021;5:e537. [PMID: 33604515 DOI: 10.1097/HS9.0000000000000537] [Reference Citation Analysis]
16 Salum KCR, Rolando JM, Zembrzuski VM, Carneiro JRI, Mello CB, Maya-Monteiro CM, Bozza PT, Kohlrausch FB, da Fonseca ACP. When Leptin Is Not There: A Review of What Nonsyndromic Monogenic Obesity Cases Tell Us and the Benefits of Exogenous Leptin. Front Endocrinol (Lausanne) 2021;12:722441. [PMID: 34504472 DOI: 10.3389/fendo.2021.722441] [Reference Citation Analysis]
17 Li H, Liu Z, Guo X, Zhang M. Circ_0128846/miR-140-3p/JAK2 Network in Osteoarthritis Development. Immunol Invest 2021;:1-19. [PMID: 34544313 DOI: 10.1080/08820139.2021.1981930] [Reference Citation Analysis]
18 Jozkowiak M, Dyszkiewicz-Konwinska M, Ramlau P, Kranc W, Spaczynska J, Wierzchowski M, Kaczmarek M, Jodynis-Liebert J, Piotrowska-Kempisty H. Individual and Combined Treatments with Methylated Resveratrol Analogue DMU-214 and Gefitinib Inhibit Tongue Cancer Cells Growth via Apoptosis Induction and EGFR Inhibition. Int J Mol Sci 2021;22:6180. [PMID: 34201116 DOI: 10.3390/ijms22126180] [Reference Citation Analysis]
19 Lizarralde-Iragorri MA, Shet AS. Sickle Cell Disease: A Paradigm for Venous Thrombosis Pathophysiology. Int J Mol Sci 2020;21:E5279. [PMID: 32722421 DOI: 10.3390/ijms21155279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zambusi A, Pelin Burhan Ö, Di Giaimo R, Schmid B, Ninkovic J. Granulins Regulate Aging Kinetics in the Adult Zebrafish Telencephalon. Cells 2020;9:E350. [PMID: 32028681 DOI: 10.3390/cells9020350] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Xu P, Shen P, Wang H, Qin L, Ren J, Sun Q, Ge R, Bian J, Zhong Y, Li Z, Wang J, Qiu Z. Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2. Eur J Med Chem 2021;218:113394. [PMID: 33813153 DOI: 10.1016/j.ejmech.2021.113394] [Reference Citation Analysis]
22 Shet AS, Lizarralde-Iragorri MA, Naik RP. The molecular basis for the prothrombotic state in sickle cell disease. Haematologica 2020;105:2368-79. [PMID: 33054077 DOI: 10.3324/haematol.2019.239350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Padda J, Khalid K, Yadav J, Almanie AH, Mehta KA, Al Hennawi H, Boddeti NL, Campos VYM, Jean-Charles G. JAK2 and TET2 Mutation in Polycythemia Vera. Cureus 2021;13:e17854. [PMID: 34660059 DOI: 10.7759/cureus.17854] [Reference Citation Analysis]
24 Nasillo V, Riva G, Paolini A, Forghieri F, Roncati L, Lusenti B, Maccaferri M, Messerotti A, Pioli V, Gilioli A, Bettelli F, Giusti D, Barozzi P, Lagreca I, Maffei R, Marasca R, Potenza L, Comoli P, Manfredini R, Maiorana A, Tagliafico E, Luppi M, Trenti T. Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. Int J Mol Sci 2021;22:1906. [PMID: 33672997 DOI: 10.3390/ijms22041906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Anderson GA, Rodriguez M, Kathrein KL. Regulation of stress-induced hematopoiesis. Curr Opin Hematol 2020;27:279-87. [PMID: 32398458 DOI: 10.1097/MOH.0000000000000589] [Reference Citation Analysis]
26 Holst JM, Enemark MB, Plesner TL, Pedersen MB, Ludvigsen M, d'Amore F. Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation. Case Rep Hematol 2021;2021:6623706. [PMID: 33953993 DOI: 10.1155/2021/6623706] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Lai F, Deng W, Fu C, Wu P, Cao M, Tan S. Long non-coding RNA SNHG6 increases JAK2 expression by targeting the miR-181 family to promote colorectal cancer cell proliferation. J Gene Med 2020;22:e3262. [PMID: 32840014 DOI: 10.1002/jgm.3262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Yang T, Hu M, Chen Y, Xiang M, Tang M, Qi W, Shi M, He J, Yuan X, Zhang C, Liu K, Li J, Yang Z, Chen L. N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. J Med Chem 2020;63:14921-36. [PMID: 33256400 DOI: 10.1021/acs.jmedchem.0c01488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Shahi A, Kahle J, Hopkins C, Diakonova M. The SH2 domain and kinase activity of JAK2 target JAK2 to centrosome and regulate cell growth and centrosome amplification. PLoS One 2022;17:e0261098. [PMID: 35089929 DOI: 10.1371/journal.pone.0261098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Song X, Tu P. Treatment of Livedoid Vasculopathy With Baricitinib. JAMA Dermatol 2022. [PMID: 35353137 DOI: 10.1001/jamadermatol.2022.0241] [Reference Citation Analysis]
31 Masselli E, Pozzi G, Gobbi G, Merighi S, Gessi S, Vitale M, Carubbi C. Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants. Cells 2020;9:E2136. [PMID: 32967342 DOI: 10.3390/cells9092136] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
32 Masselli E, Carubbi C, Pozzi G, Percesepe A, Campanelli R, Villani L, Gobbi G, Bonomini S, Roti G, Rosti V, Massa M, Barosi G, Vitale M. Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis. Cancers (Basel) 2021;13:2552. [PMID: 34067466 DOI: 10.3390/cancers13112552] [Reference Citation Analysis]
33 Veninga A, De Simone I, Heemskerk JWM, Cate HT, van der Meijden PEJ. Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding. Haematologica 2020;105:2020-31. [PMID: 32554558 DOI: 10.3324/haematol.2019.235994] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
34 Wang R, Hu X, Wang J, Zhou L, Hong Y, Zhang Y, Xiong F, Zhang X, Ye WC, Wang H. Proanthocyanidin A1 promotes the production of platelets to ameliorate chemotherapy-induced thrombocytopenia through activating JAK2/STAT3 pathway. Phytomedicine 2021;95:153880. [PMID: 34906892 DOI: 10.1016/j.phymed.2021.153880] [Reference Citation Analysis]
35 Harandi-Zadeh S, Boycott C, Beetch M, Yang T, Martin BJE, Ren K, Kwasniak A, Dupuis JH, Lubecka K, Yada RY, Howe LJ, Stefanska B. Pterostilbene Changes Epigenetic Marks at Enhancer Regions of Oncogenes in Breast Cancer Cells. Antioxidants (Basel) 2021;10:1232. [PMID: 34439480 DOI: 10.3390/antiox10081232] [Reference Citation Analysis]
36 Crodel CC, Jentsch-Ullrich K, Reiser M, Jacobasch L, Sauer A, Tesch H, Ulshöfer T, Wunschel R, Palandri F, Heidel FH. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera. J Cancer Res Clin Oncol 2021. [PMID: 34807311 DOI: 10.1007/s00432-021-03855-5] [Reference Citation Analysis]
37 Colafrancesco S, Scrivo R, Barbati C, Conti F, Priori R. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. Front Immunol 2020;11:1439. [PMID: 32655577 DOI: 10.3389/fimmu.2020.01439] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
38 Álvarez N, Rodríguez-García A, Morales ML, Gutiérrez M, Montero M, Poza M, López N, Carreño G, Sánchez R, Cedena T, Rapado I, Martínez-López J, Ayala R. Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology. Leuk Res 2021;108:106613. [PMID: 34087683 DOI: 10.1016/j.leukres.2021.106613] [Reference Citation Analysis]
39 Özenver N, Kadioglu O, Fu Y, Efferth T. Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid from Cajanus cajan (L.) Millsp. Int J Mol Sci 2022;23:1506. [PMID: 35163434 DOI: 10.3390/ijms23031506] [Reference Citation Analysis]
40 Shao X, Fu Y, Ma J, Li X, Lu C, Zhang R. Functional alterations and transcriptomic changes during zebrafish cardiac aging. Biogerontology 2020;21:637-52. [PMID: 32372324 DOI: 10.1007/s10522-020-09881-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
41 Alagpulinsa DA, Toribio MP, Alhallak I, Shmookler Reis RJ. Advances in understanding the molecular basis of clonal hematopoiesis. Trends Mol Med 2022:S1471-4914(22)00054-5. [PMID: 35341686 DOI: 10.1016/j.molmed.2022.03.002] [Reference Citation Analysis]
42 Stetka J, Gursky J, Liñan Velasquez J, Mojzikova R, Vyhlidalova P, Vrablova L, Bartek J, Divoky V. Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes. Cancers (Basel) 2020;12:E903. [PMID: 32272770 DOI: 10.3390/cancers12040903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
43 Kim M, Keam B, Ock CY, Kim SH, Kim YJ, Lim SM, Kim JS, Kim TM, Hong SH, Ahn MS, Shin SH, Kang EJ, Kim DW, Im SW, Kim JI, Lee JS, Kim JH, Heo DS. Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07. Thorac Cancer 2020;11:3482-9. [PMID: 33026712 DOI: 10.1111/1759-7714.13684] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Veletic I, Prijic S, Manshouri T, Nogueras-Gonzalez GM, Verstovsek S, Estrov Z. Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis. Haematologica 2021;106:2384-96. [PMID: 32732359 DOI: 10.3324/haematol.2020.249441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates. Molecules 2020;25:E3321. [PMID: 32707925 DOI: 10.3390/molecules25153321] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 Torres DG, Paes J, da Costa AG, Malheiro A, Silva GV, Mourão LPDS, Tarragô AM. JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms. Biomolecules 2022;12:291. [DOI: 10.3390/biom12020291] [Reference Citation Analysis]
47 Ma Q. Frequency and characteristics of the JAK2 V617F mutation in 23 cerebral venous sinus thrombosis patients with thrombocytosis. J Int Med Res 2020;48:300060520977729. [PMID: 33307939 DOI: 10.1177/0300060520977729] [Reference Citation Analysis]
48 Castiglione M, Jiang YP, Mazzeo C, Lee S, Chen JS, Kaushansky K, Yin W, Lin RZ, Zheng H, Zhan H. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. J Thromb Haemost 2020;18:3359-70. [PMID: 32920974 DOI: 10.1111/jth.15095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Hasselbalch HC, Elvers M, Schafer AI. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. Blood 2021;137:2152-60. [PMID: 33649757 DOI: 10.1182/blood.2020008109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Liu Z, Gu Y, Li X, Zhou L, Cheng X, Jiang H, Huang Y, Zhang Y, Xu T, Yang W, Huang Q. Mucin 16 Promotes Colorectal Cancer Development and Progression Through Activation of Janus Kinase 2. Dig Dis Sci 2021. [PMID: 33982216 DOI: 10.1007/s10620-021-07004-3] [Reference Citation Analysis]
51 Ravid JD, Leiva O, Chitalia VC. Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations. Cells 2022;11:306. [DOI: 10.3390/cells11020306] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
52 Zhou H, Jiang J, Lu J, Ran D, Gan Z. Synthesis and biological evaluation of novel 2,4-dianilinopyrimidine derivatives as potent dual janus kinase 2 and histone deacetylases inhibitors. Journal of Molecular Structure 2022;1253:132200. [DOI: 10.1016/j.molstruc.2021.132200] [Reference Citation Analysis]
53 Feng Y, Zhang Y, Shi J. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective. Platelets 2022;:1-9. [PMID: 35081860 DOI: 10.1080/09537104.2021.2019210] [Reference Citation Analysis]
54 Bao X, Zhu J, Ren C, Zhao A, Zhang M, Zhu Z, Lu X, Zhang Y, Li X, Sima X, Li J, Zhang Q, Ma B. β-elemonic acid inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells through the suppression of JAK2/STAT3/MCL-1 and NF-ĸB signal pathways. Chem Biol Interact 2021;342:109477. [PMID: 33878321 DOI: 10.1016/j.cbi.2021.109477] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Liu X, Tang C, Song X, Cheng L, Liu Y, Ding F, Xia C, Xue L, Xiao J, Huang B. Clinical value of CTLA4-associated microRNAs combined with inflammatory factors in the diagnosis of non-small cell lung cancer. Ann Clin Biochem 2020;57:151-61. [PMID: 31906699 DOI: 10.1177/0004563220901564] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Bruserud Ø, Vo AK, Rekvam H. Hematopoiesis, Inflammation and Aging-The Biological Background and Clinical Impact of Anemia and Increased C-Reactive Protein Levels on Elderly Individuals. J Clin Med 2022;11:706. [PMID: 35160156 DOI: 10.3390/jcm11030706] [Reference Citation Analysis]
57 Heidel F, Hochhaus A. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation. Leukemia 2020;34:1723-5. [PMID: 32528040 DOI: 10.1038/s41375-020-0898-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
58 Schnoeder TM, Perner F, Heidel FH. A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs. Mol Cell Oncol 2021;8:1871172. [PMID: 33855167 DOI: 10.1080/23723556.2020.1871172] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Tan JK, Ma XF, Wang GN, Jiang CR, Gong HQ, Liu H. LncRNA MIAT knockdown alleviates oxygen-glucose deprivation‑induced cardiomyocyte injury by regulating JAK2/STAT3 pathway via miR-181a-5p. J Cardiol 2021;78:586-97. [PMID: 34489160 DOI: 10.1016/j.jjcc.2021.08.018] [Reference Citation Analysis]